COUR Pharmaceuticals, a clinical-stage biotechnology company developing disease-modifying therapies designed to induce antigen-specific tolerance for immune-mediated diseases, entered a strategic collaboration and licensing agreement with Genentech, a member of the Roche Group, for the development and commercialization of COUR’s tolerogenic nanoparticle treatments for an autoimmune disease.   COUR is eligible for upfront and near-term milestones of $40 million, plus additional development, comm...